Psilocybin vs Ketamine Therapy

Patients researching psychedelic-assisted therapy in Canada often face the same first decision: psilocybin or ketamine? The two are genuinely different — different molecules, different mechanisms, different session structures, different access pathways, and different evidence bases by indication. Ketamine has a much larger published RCT (randomized controlled trial) base across more indications and is broadly accessible in Canada through off-label legal use plus Spravato's Health Canada-approved TRD (treatment-resistant depression) pathway. Psilocybin has a smaller RCT base concentrated in specific indications (end-of-life distress, TRD, alcohol use disorder, demoralization) and is accessible only through Health Canada's Special Access Program (SAP). Cost is in similar ranges. Insurance coverage favours ketamine more than psilocybin (Spravato has prior-auth pathways; psilocybin has Quebec RAMQ as the only public-funding precedent and VAC does not cover it). For most patients evaluating both, the practical decision is shaped by access, coverage, indication-specific evidence fit, and clinical comorbidity profile. This article walks through the honest comparison from the psilocybin-decision angle. (For the ketamine-decision angle, see Ketamine vs Psilocybin Therapy in the ketamine cluster.)

Key takeaways

• Different molecules: psilocybin is a 5-HT2A serotonin receptor agonist; ketamine is an NMDA receptor antagonist. Different drug classes, different mechanisms, different experiential profiles.
• Different access: psilocybin is SAP-only in Canada (Schedule III, no approved indication). Ketamine is broadly available off-label; Spravato is Health Canada-approved for TRD with private prior-auth coverage.
• Different evidence by indication: end-of-life distress (psilocybin stronger); TRD (ketamine larger evidence base; CANMAT 2021 task force; ELEKT-D vs ECT); AUD (psilocybin stronger at individual-trial level — Bogenschutz 2022); primary anxiety (ketamine stronger — Glue/Whittaker); chronic pain (ketamine only).
• Different session structure: psilocybin sessions are 6–8 hours with one or two dosing sessions per program; ketamine sessions are 90–120 min with 4–8 sessions per acute course.
• Cost is in similar ranges (CAD $2,500–$6,930 per program), but coverage favours ketamine — Spravato has private prior-auth pathways; psilocybin generally has no insurance coverage outside Quebec RAMQ.
• Many patients pursue both at different times — some indications are better served by one molecule, others by the other.

The molecules — fundamentally different

For mechanism deep dives: What Is Psilocybin Therapy? and What Is Ketamine Therapy?.

Access pathway — the most important practical difference

This is where most patient decisions tilt one direction or the other.

Psilocybin — SAP-only

Psilocybin clinical access in Canada requires Health Canada Special Access Program authorization. The pathway:

• A licensed physician or nurse practitioner submits a case-specific SAP request on behalf of an individual patient with a serious or life-threatening condition where conventional treatments have failed.
• Patients cannot apply directly.
• Approval timelines historically 1–4 weeks; lengthening through 2025 per PsyCan reporting.
• Once authorized, drug is sourced from a Canadian licensed producer (Filament Health, Optimi Health, Psyence Group).
• Approved indications: end-of-life distress (foundation), TRD, AUD, demoralization, cluster headache, others case-by-case.

The 2025 reality: ~301 cumulative SAP approvals since January 2022; sharp decline in 2025 monthly approvals; physician reluctance to apply remains the primary bottleneck.

For the SAP detail, see How to Access Psilocybin Therapy in Canada.

Ketamine — broadly accessible

Ketamine has multiple Canadian access pathways:

• Off-label generic ketamine (IV / IM / sublingual) at private clinics across Canada. No SAP required; physician scripts as off-label psychiatric use under provincial regulator standards (CPSA Alberta, CPSO Ontario OHPIP, CPSBC NHMSFAP, CPSS Saskatchewan NHTF).
• Spravato (intranasal esketamine): Health Canada-approved for TRD May 2020 with concurrent oral SSRI/SNRI. Janssen Journey-certified clinic; ≥2-hour observation post-dose.
• Edmonton Misericordia/Grey Nuns publicly funded IV ketamine program for ultra-resistant TRD (AHCIP-covered).

For the broader ketamine cluster, see the Ketamine Therapy in Canada hub.

The honest practical takeaway: ketamine is broadly accessible across Canada within weeks; psilocybin requires SAP authorization that may take weeks-to-months and may not be approved.

Session structure — meaningful differences

The "long psilocybin day vs the short ketamine session" is a meaningful patient-experience difference. Patients with limited capacity for long days (chronic illness, family responsibilities) may find ketamine's shorter format more practical. Patients prioritizing depth of experience and meaning-making may find psilocybin's longer container more therapeutically rich.

Evidence comparison by indication

This is where the comparison becomes indication-specific.

End-of-life distress — psilocybin stronger

• Psilocybin: foundational evidence (Griffiths 2016 N=51, Ross 2016 N=29, Agin-Liebes 2020 long-term follow-up, Agrawal 2024 group format). The strongest published evidence base in psychedelic medicine for any condition.
• Ketamine: limited end-of-life-specific evidence; some pain-management literature; not the established option for end-of-life distress.

Winner for end-of-life: psilocybin.

Treatment-resistant depression — ketamine larger; psilocybin growing

• Ketamine: extensive RCT base (Berman 2000, Zarate 2006, Murrough 2013, Singh 2016, Phillips 2019, ELEKT-D 2023 NEJM non-inferior to ECT, Spravato pivotal trials Daly 2018, Popova 2019, Wajs 2020). CANMAT 2021 task force recommendation as third-line.
• Psilocybin: meaningful evidence (Carhart-Harris 2016, Davis 2021, Carhart-Harris 2021 NEJM vs escitalopram, Goodwin 2022 NEJM COMP001 N=233). Evidence base is real but smaller in scale; CANMAT does not yet include psilocybin in TRD recommendations.

For most TRD patients in 2026 Canada, ketamine is the more accessible and better-supported option, particularly Spravato for those with private prior-auth coverage. Psilocybin SAP for TRD is a real pathway for patients willing to navigate the regulatory process.

For detail: Psilocybin Therapy for TRD and Ketamine Therapy for TRD (deep dive).

Alcohol use disorder — psilocybin stronger

• Psilocybin: Bogenschutz 2022 JAMA Psychiatry RCT (N=95) — heavy drinking days 9.7% vs 23.6% over 32 weeks. The cleanest published psychedelic SUD trial.
• Ketamine: Krupitsky historical work, Dakwar 2020, KARE/Grabski 2022 (N=96) — meaningful evidence, but Bogenschutz's design and effect size are stronger.

Winner for AUD specifically: psilocybin at the individual-trial level — but ketamine's broader access often wins the practical decision.

For detail: Psilocybin Therapy for AUD and Ketamine Therapy for Addiction.

Primary anxiety — ketamine stronger

• Ketamine: Glue 2017/2018/2020 GAD/SAD trials, Taylor 2018 SAD RCT, Whittaker 2021 meta-analysis with pooled SAD OR 28.94. Meaningful primary-anxiety evidence.
• Psilocybin: most evidence is cancer-related anxiety (Griffiths 2016, Ross 2016) within end-of-life trials. Primary GAD/SAD evidence is preliminary.

Winner for primary anxiety: ketamine.

For detail: Ketamine Therapy for Anxiety and Psilocybin Therapy for Anxiety.

PTSD — ketamine; MDMA-AT context

• Ketamine: Feder 2014/2021 RCTs, recent meta-analyses (Du 2022, Sicignano 2024, Bryant 2024). Modest but real.
• Psilocybin: limited PTSD-specific evidence. PTSD-specific Canadian SAP applications more commonly target MDMA-assisted therapy.
• MDMA-AT: Mitchell 2021/2023 Phase 3 trials show stronger PTSD-specific RCT effect sizes (~d=1.0). FDA declined approval August 2024; Canadian access is SAP-only.

Winner for PTSD specifically: among approved/SAP options, ketamine has more accessible Canadian pathways; MDMA has stronger evidence but tighter access.

For detail: Ketamine Therapy for PTSD.

Chronic pain — ketamine only

• Ketamine: ASRA 2018 consensus guidelines; CRPS evidence (Sigtermans 2009, Schwartzman 2009, Goldberg 2005); refractory neuropathic pain literature.
• Psilocybin: minimal chronic pain evidence; not an established pain-medicine indication in 2026.

Winner for chronic pain: ketamine. See Ketamine Therapy for Chronic Pain.

Demoralization — psilocybin stronger

• Psilocybin: Anderson 2020 EClinicalMedicine pilot specifically in demoralization; cancer trials report demoralization-relevant outcomes.
• Ketamine: limited demoralization-specific evidence.

Winner for demoralization: psilocybin. See Psilocybin Therapy for Demoralization.

Cost — similar ranges, different coverage realities

The honest cost takeaway: for most Canadian patients with private benefits, ketamine (particularly Spravato) is the more affordable pathway by net out-of-pocket. Psilocybin is roughly comparable in list price but lacks insurance coverage outside Quebec.

For detail: Psilocybin-Assisted Therapy Cost in Canada and Ketamine Therapy Cost in Canada.

How to think about the decision

A practical framing for patients evaluating both pathways:

Choose psilocybin if:

• Indication is end-of-life distress, demoralization in serious illness, or AUD where psilocybin's evidence is strongest
• Quebec resident with eligible RAMQ pathway
• Comfortable with the SAP application timeline and access uncertainty
• Drawn to the longer-format dosing experience and mystical-type therapeutic frame
• Willing to pay out-of-pocket where insurance does not apply

Choose ketamine if:

• Indication is primary anxiety, PTSD, chronic pain, or TRD without specific psilocybin preference
• Need access within weeks rather than months
• Have private benefits supporting Spravato prior auth
• Are a veteran with VAC eligibility
• Are an injured worker with WSIB or WCB eligibility
• Prefer shorter (90–120 min) sessions with more frequent dosing
• Live somewhere SAP-pathway clinicians are not locally available

Consider both at different times:

• Some patients benefit from one acute pathway and later add the other (e.g., ketamine acute course for TRD; psilocybin SAP later for demoralization or end-of-life work)
• ATMA CENA's intake call discusses sequencing where appropriate

How ATMA CENA supports both pathways

ATMA CENA's clinical model adapts to both:

• Ketamine: ATMA CENA's corporate clinics in Edmonton and Calgary deliver KAT (ketamine-assisted therapy) primarily through IM and sublingual ketamine. coordinated care arrangements support patients pursuing IV-led care or Spravato through external Janssen Journey-certified providers.
• Psilocybin: ATMA CENA supports preparation and integration for SAP-pathway patients in coordination with the patient's prescribing physician. The medical SAP application is initiated by the prescribing physician, not ATMA CENA directly.
• The intake call discusses both pathways honestly. For some indications and patient situations, one pathway is clearly the right fit; for others, both are legitimate options.

Frequently asked questions

Is psilocybin or ketamine more effective for depression? For TRD specifically, ketamine has the larger published RCT base and CANMAT 2021 task force recommendation. Psilocybin has meaningful but smaller evidence (Goodwin 2022 N=233; Davis 2021 N=24). Both work; the practical answer in 2026 Canada often turns on access and coverage.

Is psilocybin or ketamine better for end-of-life patients? Psilocybin has the strongest published end-of-life distress evidence — Griffiths 2016, Ross 2016, Agin-Liebes 2020. End-of-life is the foundation Canadian SAP indication.

Which is more accessible in Canada? Ketamine. Off-label legal availability across Canada plus Spravato's Health Canada-approved TRD pathway plus VAC and workers' comp coverage all make ketamine substantially more accessible than psilocybin.

Which costs more out-of-pocket? Similar list prices (CAD $2,500–$6,930 per program). For patients with private benefits, ketamine — particularly Spravato — typically costs less net out-of-pocket because of insurance coverage.

Can I do both? Yes. Some patients pursue ketamine for one indication and psilocybin for another, or sequence them at different times. ATMA CENA's intake discusses sequencing where appropriate.

What about psilocybin for primary anxiety? The evidence is preliminary outside cancer-related contexts. Ketamine has more established primary-anxiety evidence (Glue/Whittaker). For primary GAD/SAD without comorbid serious illness, ketamine is generally the better-evidenced option.

What about psilocybin for AUD? Psilocybin has the cleanest published RCT for AUD (Bogenschutz 2022 N=95). Ketamine's AUD evidence is meaningful but less rigorous. Both require active SUD as a contraindication and abstinence-stabilization first.

Does ATMA CENA offer both? ATMA CENA's corporate clinics deliver KAT primarily through IM and sublingual ketamine. Psilocybin SAP-pathway support is via coordinated care and integration. Confirm specific scope at intake.

What's the difference experientially? Psilocybin: classic psychedelic — visuals, ego dissolution, mystical experience, longer (6–8 hour) session. Ketamine: dissociative — softening of body awareness, time distortion, shorter (90–120 min) session. Both can produce profound therapeutic experiences; the specific phenomenology differs.

Which has more long-term safety data? Ketamine — Wajs 2020 SUSTAIN-2 (N=802 over 1 year). Psilocybin's longest published follow-up data is Agin-Liebes 2020 at 4–5 years in the Ross cancer cohort, but the sample is smaller. Both are generally well-tolerated at therapeutic supervised doses.

What if my indication isn't on either evidence list? Many patients have indications without large RCT bases for either substance. The ATMA CENA intake discusses what evidence exists, what conventional alternatives have been tried, and what realistic next steps look like.

Sources

1. ATMA CENA — find care near you: https://psychedelic.healthcare/find-care
2. Health Canada — SAP psychedelic-assisted psychotherapy: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/requests-special-access-program-psychedelic-assisted-psychotherapy.html
3. Goodwin GM, et al. (2022). Psilocybin in TRD COMP001 Phase 2b. NEJM. https://pubmed.ncbi.nlm.nih.gov/36322843/
4. Griffiths RR, et al. (2016). Psilocybin in life-threatening cancer. J Psychopharmacol. https://pubmed.ncbi.nlm.nih.gov/27909164/
5. Bogenschutz MP, et al. (2022). Psilocybin-assisted treatment for AUD. JAMA Psychiatry. https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2795625
6. Anderson BT, et al. (2020). Psilocybin-assisted group therapy for demoralization. EClinicalMedicine. https://pubmed.ncbi.nlm.nih.gov/33150319/
7. Anand A, et al. (2023). Ketamine vs ECT for TRD: ELEKT-D. NEJM. https://pubmed.ncbi.nlm.nih.gov/37224135/
8. Swainson J, et al. (2021). CANMAT racemic ketamine task force recommendations. Can J Psychiatry. https://pubmed.ncbi.nlm.nih.gov/33174760/
9. Wajs E, et al. (2020). SUSTAIN-2 long-term Spravato safety. J Clin Psychiatry. https://pubmed.ncbi.nlm.nih.gov/32316080/
10. Whittaker E, et al. (2021). Meta-analysis of ketamine for refractory anxiety. Ther Adv Psychopharmacol. https://pubmed.ncbi.nlm.nih.gov/34925757/
11. Feder A, et al. (2021). Repeated ketamine for chronic PTSD RCT. Am J Psychiatry. https://pubmed.ncbi.nlm.nih.gov/37404970/
12. Cohen SP, et al. (2018). Consensus guidelines on IV ketamine for chronic pain (ASRA/AAPM/ASA). Reg Anesth Pain Med. https://pubmed.ncbi.nlm.nih.gov/29870458/
13. Health Canada DPD — Spravato: https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98903

Related articles

• Psilocybin Therapy in Canada
• What Is Psilocybin Therapy?
• How to Access Psilocybin Therapy in Canada (SAP)
• Psilocybin-Assisted Therapy Cost in Canada
• Psilocybin Therapy for End-of-Life Distress
• Psilocybin Therapy for TRD
• Psilocybin Therapy for AUD
• Psilocybin Therapy for Anxiety
• Psilocybin Therapy for Demoralization
• Ketamine Therapy in Canada
• Ketamine vs Psilocybin Therapy
• Find care near you

Last updated: 2026-05-06